Passage Bio Valuation
| PASG Stock | USD 9.12 0.46 5.31% |
At this time, the company appears to be undervalued. Passage Bio holds a recent Real Value of $16.65 per share. The prevailing price of the company is $9.12. Our model determines the value of Passage Bio from analyzing the company fundamentals such as Shares Outstanding of 3.18 M, return on equity of -0.87, and Shares Owned By Institutions of 52.08 % as well as examining its technical indicators and probability of bankruptcy. Key fundamental drivers impacting Passage Bio's valuation include:
Undervalued
Today
Please note that Passage Bio's price fluctuation is slightly risky at this time. Calculation of the real value of Passage Bio is based on 3 months time horizon. Increasing Passage Bio's time horizon generally increases the accuracy of value calculation and significantly improves the predictive power of the methodology used.
The fair value of the Passage stock is determined by what a typical buyer is willing to pay for full or partial control of Passage Bio. Since Passage Bio is currently traded on the exchange, buyers and sellers on that exchange determine the market value of Passage Stock. However, Passage Bio's intrinsic value may or may not be the same as its current market price, in which case there is an opportunity to profit from the mispricing, assuming the market price will eventually merge with its intrinsic value. | Historical | Market 9.12 | Real 16.65 | Target 39.6 | Hype 8.88 | Naive 10.24 |
The real value of Passage Stock, also known as its intrinsic value, is the underlying worth of Passage Bio Company, which is reflected in its stock price. It is based on Passage Bio's financial performance, growth prospects, management team, or industry conditions. The intrinsic value of Passage Bio's stock can be calculated using various methods such as discounted cash flow analysis, price-to-earnings ratio, or price-to-book ratio. That value may differ from its current market price, which is determined by supply and demand factors such as investor sentiment, market trends, or news.
Estimating the potential upside or downside of Passage Bio helps investors to forecast how Passage stock's addition to their portfolios will impact the overall performance. We also use other valuation drivers to help us estimate the true value of Passage Bio more accurately as focusing exclusively on Passage Bio's fundamentals will not take into account other important factors: When choosing an evaluation method for Passage Bio, ensure it is appropriate for the firm given its current financial situation and market classification. If more than one evaluation category is relevant, we suggest using all methods to arrive at a better estimate.
Passage Bio Cash |
|
Passage Bio Total Value Analysis
Passage Bio is at this time projected to have valuation of 426.69 K with market capitalization of 28.99 M, debt of 25.48 M, and cash on hands of 239.25 M. Please note that valuation may be misleading and is a subject to auditing or accounting errors. We encourage investors to vigilantly validate all of the Passage Bio fundamentals before making equity appraisal based on enterprise value of the company| Takeover Price | Market Cap | Debt Obligations | Cash |
426.69 K | 28.99 M | 25.48 M | 239.25 M |
Passage Bio Asset Utilization
One of the ways to look at asset utilization of Passage is to check how much profit was generated for every dollar of assets it reports. Passage Bio holds a negative application of assets of -0.32 pct., losing $0.003166 for each dollar of assets held by the company. Inadequate asset utilization implies the company is being less effective with each dollar of assets it holds. Put it differently, asset utilization of Passage Bio shows how discouraging it operates for each dollar spent on its assets.Passage Bio Profitability Analysis
Considering Passage Bio's profitability and operating efficiency indicators, Passage Bio may not be well positioned to generate adequate gross income at this time. It has a very high odds of underperforming in April. Profitability indicators assess Passage Bio's ability to earn profits and add value for shareholders.Net Loss | First Reported 2018-12-31 | Previous Quarter -9.4 M | Current Value -7.7 M | Quarterly Volatility 13.5 M |
For Passage Bio profitability analysis, we use financial ratios and fundamental drivers that measure the ability of Passage Bio to generate income relative to revenue, assets, operating costs, and current equity. These fundamental indicators attest to how well Passage Bio utilizes its assets to generate profit and value for its shareholders. The profitability module also shows relationships between Passage Bio's most relevant fundamental drivers. It provides multiple suggestions of what could affect the performance of Passage Bio over time as well as its relative position and ranking within its peers.
Passage Bio Earnings per Share Projection vs Actual
By analyzing Passage Bio's earnings estimates, investors can diagnose different trends across Passage Bio's analyst sentiment over time as well as compare current EPS estimates against different timeframes. Please be aware that the consensus of earnings estimates for Passage Bio is based on EPS before non-recurring items and includes expenses related to employee stock options.Passage Bio Ownership Allocation
The market capitalization of Passage Bio is $28.99 Million. Over half of Passage Bio's outstanding shares are owned by third-party entities. These third-party entities are typically referred to as corporate investors that secure positions in a given instrument to benefit from reduced trade commissions. Note, that even with negative profits, if the true value of the company is larger than the current market value, you may still be able to generate positive returns on investment in this company.Passage Bio Profitability Analysis
Net Loss for the year was (64.77 M) with profit before overhead, payroll, taxes, and interest of 0.Please note that valuation analysis is one of the essential comprehensive assessments in business. It evaluates Passage Bio's worth, which you can determine by considering its current assets, liabilities and future cash flows. The investors' valuation analysis is an important metric that will give you a perspective on different companies. It helps you know the worth of the potential investment in Passage Bio and how it compares across the competition.
About Passage Bio Valuation
The stock valuation mechanism determines Passage Bio's current worth on a weekly basis. Our valuation model uses a comparative analysis of Passage Bio. We calculate exposure to Passage Bio's market risk, different technical and fundamental indicators, and relevant financial multiples and ratios and then compare them to those of Passage Bio's related companies.| Last Reported | Projected for Next Year | ||
| Gross Profit | -2.8 M | -2.9 M |
Passage Bio Current Valuation Indicators
Valuation refers to the process of determining the present value of Passage Bio and all of its assets. It can be calculated using a number of techniques. As many analysts who try to value Passage we look at many different elements of the entity such as Passage's management, its prospective future earnings, the current market value of the company's assets, as well as its capital structure formation.
Valuations are an essential part of business, for companies themselves, but also for investors. For companies, such as Passage Bio, valuations can help measure their progress and success and can help them track their performance in the market compared to others. In addition, investors can use Passage Bio's valuations to help determine the worth of potential investments. They can do this by using data and information made public by a company. Regardless of who the valuation is for, it essentially describes Passage Bio's worth.Complementary Tools for Passage Stock analysis
When running Passage Bio's price analysis, check to measure Passage Bio's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Passage Bio is operating at the current time. Most of Passage Bio's value examination focuses on studying past and present price action to predict the probability of Passage Bio's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Passage Bio's price. Additionally, you may evaluate how the addition of Passage Bio to your portfolios can decrease your overall portfolio volatility.
| Portfolio Backtesting Avoid under-diversification and over-optimization by backtesting your portfolios | |
| Portfolio Center All portfolio management and optimization tools to improve performance of your portfolios | |
| Transaction History View history of all your transactions and understand their impact on performance | |
| Portfolio Comparator Compare the composition, asset allocations and performance of any two portfolios in your account | |
| Investing Opportunities Build portfolios using our predefined set of ideas and optimize them against your investing preferences | |
| Portfolio Anywhere Track or share privately all of your investments from the convenience of any device | |
| Portfolio Manager State of the art Portfolio Manager to monitor and improve performance of your invested capital | |
| Risk-Return Analysis View associations between returns expected from investment and the risk you assume | |
| Instant Ratings Determine any equity ratings based on digital recommendations. Macroaxis instant equity ratings are based on combination of fundamental analysis and risk-adjusted market performance |